Inverness prices $132.5 million convertibles at 3%, up 30%

New York, May 9 - Inverness Medical Innovations, Inc. priced a $132.5 million offering of convertible senior subordinated notes due 2017 to yield 3% with a 30% initial conversion premium.

The conversion price is $52.30 but can be adjusted after a year if the 30-day volume-weighted average trading price of the company's stock is lower than $40.23, the closing price on Wednesday. The conversion price adjustment will have a floor of $40.23.

Inverness priced the Rule 144A offering after the close Wednesday.

Proceeds will be used for general corporate purposes including acquisitions.

Separately after the close Wednesday, the Waltham, Mass., developer of in vitro diagnostic products announced a new offer for Biosite Inc. of $92.50 a share, $2.50 more than previously.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.